Patients should be provided with written educational material about aspects of their care (including glucocorticoid taper and other immunosuppressive drugs).[111]Coath FL, Bukhari M, Ducker G, et al. Quality standards for the care of people with giant cell arteritis in secondary care. Rheumatology (Oxford). 2023 Sep 1;62(9):3075-83.
http://www.ncbi.nlm.nih.gov/pubmed/36692142?tool=bestpractice.com
Patients should have the opportunity to speak to a health professional about the condition within one month of diagnosis and receive updates as needed.[111]Coath FL, Bukhari M, Ducker G, et al. Quality standards for the care of people with giant cell arteritis in secondary care. Rheumatology (Oxford). 2023 Sep 1;62(9):3075-83.
http://www.ncbi.nlm.nih.gov/pubmed/36692142?tool=bestpractice.com